TAIPEI, Jan. 31, 2024 /PRNewswire/ -- Anbogen Therapeutics, a clinical-stage biotechnology company ...
An oral Tyrosine Kinase Inhibitor of HER2 Exon20 Insertion, for the Treatment of Non-Small Cell Lu...
